SanBio Receives FDA Clearance to Initiate Cell Therapy Clinical Studies for Stroke Recovery

Bio-Medicine.Org

MOUNTAIN VIEW, Calif., June 16 /PRNewswire/ -- SanBio Inc. (www.san-bio.com [1]) announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

This Phase 1/2a clinical trial will test the safety of SB623 when implanted in the damaged regions of the brains of stable stroke patients. "We are pleased and proud to be given the opportunity to move this therapeutic approach forward. This is the only clinical trial currently open in the United States testing the regenerative potential of cell therapy in the brain," said Kieta Mori, co-CEO of SanBio. "This cell product has the potential to change the lives of patients afflicted by stroke injury," said Dr. Douglas Kondziolka [2], the Peter J. Jannetta Professor of Neurological Surgery in the Department of Neurological Surgery, Director, Center for Brain Function and Behavior at the University of Pittsburgh School of Medicine and a Principal Investigator in the SB623 clinical trial. According to the American Heart Association, stroke is the third leading cause of death in the United States and the leading c
'/>"/>

SOURCE [3]

Source URL (retrieved on *01/26/2015 - 2:19am*):
http://www.mdtmag.com/news/2010/06/sanbio-receives-fda-clearance-initiate-cell-therapy-clinical-studies-stroke-recovery

Links:
[1] http://www.san-bio.com/
[2] http://www.neurosurgery.pitt.edu/faculty/kondziolka.html
[3] http://www.bio-medicine.org/medicine-technology-1/SanBio-Receives-FDA-Clearance-to-Initiate-Cell-Therapy-Clinical-Studies-for-Stroke-Recovery-9317-1/